Public trial registry of the CCC-Munich

Trial IMMUWIN

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
IMMUWIN
World
Full title
:

A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

World
Responsible organization
:
2. Med 2. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Livertumor
Trial design
World
Phase
:
II
Status
World
Status
:
Recruitment active
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo

Participants
Function Prename Surname Organization
World Responsible contact Ursula Ehmer 2. Med 2. Med Ismaninger Str. 22 81675 München Germany Magnifier